Biotinylated Human LILRB4 / CD85k / ILT3 Protein, His,Avitag™ (MALS verified)
分子别名(Synonym)
LILRB4,ILT3,LIR5,CD85K,HM18
表达区间及表达系统(Source)
Biotinylated Human LILRB4, His,Avitag (LI4-H82E4) is expressed from human 293 cells (HEK293). It contains AA Gln 22 - Glu 259 (Accession # AAH26309.1).
Predicted N-terminus: Gln 22
蛋白结构(Molecular Characterization)
![1.jpg 1.jpg](/SupplyImg1/2024-07-30/6385794309645560686019370.jpg)
This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).
The protein has a calculated MW of 29.8 kDa. The protein migrates as 32-40 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
标记(Labeling)
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
蛋白标记度(Protein Ratio)
Passed as determined by the HABA assay / binding ELISA.
内毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
纯度(Purity)
>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制剂(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
![2.jpg 2.jpg](/SupplyImg1/2024-07-30/6385794311021307712289559.jpg)
![3.jpg 3.jpg](/SupplyImg1/2024-07-30/6385794311351148246215907.jpg)
背景(Background)
白细胞免疫球蛋白样受体亚家族B成员4(LILRB4)也称为CD85抗原样家族成员K(CD85K)、免疫球蛋白类转录物3(ILT-3)、白细胞免疫珠蛋白样受体5(LIR-5)、单核细胞抑制受体HM18,属于白细胞免疫标球蛋白样接收器(LIR)家族。LILRB4/CD85K含有2个Ig样C2型(免疫球蛋白样)结构域。在单核细胞、巨噬细胞、树突状细胞、肺、自然杀伤细胞和B细胞中检测到CD85K。LILRB4/CD85K是I类MHC抗原的受体。CD85K识别广泛的HLA-a、HLA-B、HLA-C和HLA-G等位基因,参与免疫反应的下调和耐受的发展。LILRB4干扰TNFRSF5信号传导和NF-kappa-B上调,并抑制受体介导的细胞蛋白磷酸化和细胞内钙离子的动员。
关键字: LILRB4;LILRB4蛋白;LILRB4重组蛋白;ACRO;百普赛斯;
百普赛斯集团ACROBiosystems Group(股票代码:301080)是成立于2010年的跨国生物科技公司,是为全球生物医药、健康产业领域提供关键生物试剂产品及解决方案的行业平台型基石企业。2021年在创业板上市。百普赛斯集团业务遍布全球,横跨亚洲、北美洲、欧洲,在中国、美国、瑞士等12个城市设有办公室、研发中心及生产基地。目前累计服务客户超6000家,与全球Top 20医药企业均建立了长期、稳定的合作伙伴关系。集团旗下拥有品牌ACROBiosystems百普赛斯、bioSeedin柏思荟、Condense Capital垦拓资本和ACRODiagnostics百斯医学等。